Nilo Reyes
Family · Bellflower, CANPI 1770117020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 24.2% of the total. Reporting peaked in 2021 at $1,715 and has fallen 56.8% since, to $742 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$716
- AstraZeneca$642
- Boehringer Ingelheim$317
- Lilly USA, LLC$278
- Bayer$201
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,258100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $1,030 |
| GSK | 27 | $716 |
| AstraZeneca | 26 | $642 |
| Boehringer Ingelheim | 10 | $317 |
| Lilly USA, LLC | 14 | $278 |
| Bayer | 7 | $201 |
| AbbVie | 5 | $167 |
| Amarin Pharma, Inc. | 10 | $147 |
| Teva Pharmaceuticals USA, Inc. | 2 | $142 |
| Amgen | 6 | $130 |
| Merck | 5 | $104 |
| Xeris Pharmaceuticals, Inc. | 3 | $61 |
| Johnson & Johnson | 2 | $61 |
| Pfizer | 3 | $56 |
| Sanofi | 1 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Genentech USA, Inc. | 1 | $23 |
| Gilead | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$236
- ProAir Digihaler$122
- ArmonAir Digihaler$122
- AirDuo RespiClick$122
- Ozempic$122
- JARDIANCE$122
- Wegovy$119
- TRELEGY ELLIPTA$119
- Kerendia$114
- BREZTRI$105
How this compares
$4,258 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $44,346 |
| FarxigaDapagliflozin Propanediol | 13 | $16,367 |
| JardianceEmpagliflozin | 11 | $12,836 |
| JanuviaSitagliptin Phosphate | 19 | $11,347 |
| VascepaIcosapent Ethyl | 12 | $5,464 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $690 |
| NitrofurantoinNitrofurantoin Macrocrystal | 11 | $636 |
| Atorvastatin Calcium | 85 | $533 |
| Rosuvastatin Calcium | 21 | $401 |
| Fluticasone Propionate | 28 | $400 |
| Levothyroxine Sodium | 22 | $376 |
| Losartan Potassium | 61 | $354 |
| Metoprolol Succinate | 31 | $339 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 21 | $291 |
| Amlodipine Besylate | 43 | $283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,030 | $44,34642 claims |
| AstraZenecaFarxiga | $642 | $16,36713 claims |
| Boehringer IngelheimJardiance | $317 | $12,83611 claims |
| MerckJanuvia | $104 | $11,34719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Bellflower
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.